Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04201418 · ClinicalTrials.gov registry record
A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation
A clinical trial of Polyneuropathy and Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- 67
- Enrollment target
- 20
- Study locations
NCT04201418 is a study of Polyneuropathy and Hereditary Transthyretin-mediated (ATTRv) Amyloidosis that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 67 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT04201418, a study of Polyneuropathy and Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the effectiveness of patisiran in patients with ATTRv amyloidosis with polyneuropathy who have a V122I or T60A mutation.
Conditions Studied
Interventions
- DRUG Patisiran
Study Locations (20)
California
- Clinical Trial Site - Los Angeles
- Clinical Trial Site - San Diego
Florida
- Clinical Trial Site - Jacksonville
- Clinical Trial Site - Tampa
Georgia
- Clinical Trial Site - Braselton
- Clinical Trial Site - Macon
Illinois
- Clinical Trial Site - Chicago
- Clinical Trial Site - Chicago
North Carolina
- Clinical Trial Site - Chapel Hill
- Clinical Trial Site - Charlotte
Pennsylvania
- Clinical Trial Site - Allentown
- Clinical Trial Site - Bethlehem
Colorado
- Clinical Trial Site - Aurora
Connecticut
- Clinical Trial Site - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2019-12-18 |
| Est. Completion | 2022-05-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04201418
The ClinicalTrials.gov registry entry for NCT04201418 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Polyneuropathy appearing as the primary indexed condition, and to 1 intervention - of which Patisiran is the first listed.
NCT04201418 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT04201418 about?
NCT04201418 is a clinical study titled "A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation". To evaluate the effectiveness of patisiran in patients with ATTRv amyloidosis with polyneuropathy who have a V122I or T60A mutation.
What is the current status of trial NCT04201418?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2019-12-18. Estimated completion is 2022-05-24.
What conditions does trial NCT04201418 study?
This clinical trial studies the following conditions: Polyneuropathy, Hereditary Transthyretin-mediated (ATTRv) Amyloidosis.
What interventions are being tested in trial NCT04201418?
The interventions under investigation include: Patisiran (DRUG).
Who is sponsoring clinical trial NCT04201418?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04201418 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Polyneuropathy
All registered trials for this condition
Hereditary Transthyretin-mediated (ATTRv) Amyloidosis
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.